Plasma Cell Neoplasms (Including Multiple Myeloma) Research
FDA Approves New Use for Lenalidomide in Multiple MyelomaPosted: March 16, 2017
The FDA has approved lenalidomide for use as a maintenance therapy in patients with multiple myeloma who have undergone an autologous stem cell transplant, to help keep the cancer from coming back.
Three-Drug Combination Extends Survival for Patients with Multiple MyelomaPosted: February 10, 2017
A phase III clinical trial demonstrates that adding the drug bortezomib to a commonly used two-drug regimen extends survival in patients with newly diagnosed multiple myeloma.
Daratumumab Improves Progression-Free Survival for Patients with Multiple MyelomaPosted: January 4, 2017
Results from a phase III trial showed that adding daratumumab to lenalidomide and dexamethasone improved progression-free survival among patients with relapsed or refractory disease, compared with lenalidomide and dexamethasone alone.
Single Tumor Cells Reveal Clues to Biology of Multiple MyelomaPosted: December 13, 2016
A study suggests that individual tumor cells circulating in the blood of patients with multiple myeloma may be a new source of information about the genetic changes driving the disease.
FDA Approves New Use for Daratumumab in Multiple MyelomaPosted: December 9, 2016
The FDA has approved daratumumab, in combination with either of two other standard therapies, in patients with multiple myeloma whose disease has progressed after only a single prior treatment course.
Three New Therapies Approved for Multiple MyelomaPosted: January 6, 2016
In November 2015, the FDA approved three new therapies for patients with multiple myeloma.
FDA Approves Expanded Indication for Carfilzomib in Patients with Multiple MyelomaPosted: August 24, 2015
The FDA has approved carfilzomib in combination with other anticancer drugs to treat patients with relapsed multiple myeloma.
Three-Drug Combination Benefits Some Patients with Relapsed Multiple MyelomaPosted: January 9, 2015
Interim results from an international, randomized phase III trial suggest that adding carfilzomib (Kyprolis®) to a standard treatment improves outcomes for patients with multiple myeloma whose cancer has relapsed. Participants in the study who received carfilzomib plus lenalidomide (Revlimid®) and dexamethasone lived a median of 8.7 months longer without the disease getting worse than patients who received lenalidomide and dexamethasone alone.
Pomalidomide plus Low-Dose Dexamethasone Improves Survival for Patients with Multiple MyelomaPosted: September 19, 2013
Results from a randomized phase III trial show that the combination of pomalidomide (Pomalyst®) and low-dose dexamethasone may benefit some patients with multiple myeloma that has progressed (worsened) despite other treatments. Patients who received the combination therapy lived longer without the disease getting worse than patients who received high-dose dexamethasone alone. Overall survival was also improved in the group that received the combination therapy compared with the other group.
Treating Patients with High-Risk Smoldering MyelomaPosted: December 11, 2012
In this phase III clinical trial, patients with smoldering myeloma classified as high risk for progression will be randomly assigned to undergo standard observation or six 4-week courses of treatment with the drug lenalidomide.
Denosumab Effective for Multiple Myeloma and Solid TumorsPosted: June 8, 2011
Results from a randomized phase III trial of denosumab to prevent skeletal related events in several types of cancer were published online February 22, 2011, in the Journal of Clinical Oncology (JCO).